Stereotaxis Completes Acquisition of Robocath

July 13, 2026—Stereotaxis announced that it has completed its previously announced acquisition of Robocath, a Rouen, France-based developer of robotic technologies for interventional cardiology and neurointerventions.

First Patient Enrolled in ENHANCE EFS of Nyra’s Carlen TMVR System for FMR

July 10, 2026—Nyra Medical, Inc. announced enrollment of the first patient in the ENHANCE early feasibility study (EFS) of the company’s investigational Carlen system.

TRICURE US Pivotal Study Begins for TriCares’ Topaz TTVR System

July 10, 2026—TriCares SAS announced that the first patient has been enrolled and treated in the TRICURE United States investigation device exemption (IDE) pivotal study, which is evaluating the company’s Topaz transcatheter tricuspid valve replacement (TTVR) system in the treatment of tricuspid regurgitation (TR).

GLP-1 RAs Linked to Lower Mortality, Amputation Risk in PAD and Type 2 Diabetes

July 6, 2026—Glucagon‐like peptide‐1 receptor agonists (GLP-1 RAs) were shown to be associated with lower risks of death, hospitalization, amputation, and lower-extremity revascularization compared with metformin among adults with type 2 diabetes and peripheral artery disease (PAD), according to the American Heart Association.

Egg Medical Launches EggNest Complete 2.0 Radiation Protection Device  

July 6, 2026—Egg Medical, a developer of enhanced radiation protection devices (ERPDs) for interventional procedures, announced the launch of its next-generation EggNest Complete 2.0 system.

Arizona Enacts Law on Radiation Protection Systems for Health Care Workers

July 6, 2026—A state law addressing the safety of staff in medical procedures involving ionizing radiation, lead aprons, radiation protection systems, and real-time dosimeters was enacted by Arizona Governor Kathy Hobbs on June 19.

IDE for TRIUMPH Pivotal Trial of Laplace’s TTVR System

July 2, 2026—Laplace Interventional, Inc. announced that the FDA has approved an investigational device exemption (IDE) for the TRIUMPH pivotal trial evaluating the company’s transcatheter tricuspid valve replacement (TTVR) system.

GE’s Allia Upgrade Pathways Introduced for Existing Interventional Suites

June 30, 2026—GE HealthCare announced the introduction of Allia platform upgrade pathways that are designed to help customers modernize select legacy Innova and Discovery image guiding solutions (IGS) systems.